Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL
William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.
Source: onclive.com
Williamb Pearse News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Williamb Pearse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Williamb Pearse Today - Breaking & Trending Today
Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL
William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.
Source: onclive.com
Dr Pearse on the Use of BTK Inhibitors in Relapsed/Refractory MCL
William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.
Source: onclive.com
Pirtobrutinib Expands MCL Armamentarium, Although Sequencing Questions Remain
William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.
Source: onclive.com
BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL
William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.
Source: onclive.com